Dr Lal PathLabs records revenue growth of 0.2% to Rs 301.7 Cr in Q4 FY 2019-20

Normalised EBITDA ex Ind AS 116 at Rs 55.5 Cr

Dr Lal PathLabs, Revenue growth, Diagnostics, Financial results, EBITDA

Dr LathLabs Limited, a leading diagnostic and related healthcare service provider, has announced their financial results for the quarter ended March 31, 202. The highlights are:

·         Operating Revenue increased by 0.2% in Q4 FY20 to Rs. 301.7 Cr vs Rs 301.1 Cr in the previous year same quarter. Underlying patient volume growth is 2.1% during the quarter
·         Normalised EBITDA (after adjustment for stock based compensation, CSR cost & impact of Ind AS 116)  for Q4 FY20 is at Rs. 55.5 Cr Vs Rs 72.9 Cr in the same quarter last year

·         PBT is at Rs 45.4 Cr in Q4 FY20 vs Rs 69.2 Cr. in Q4 last year
·         Profit after Tax in Q4 FY20 at Rs. 32.6 Cr as compared to Rs 47.4 Cr in Q4 last year
As on March 31, 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers.